Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atomoxetine in Mild Cognitive Impairment
NCT01522404Phase 2Completed
- Sponsor
- Emory University
- Start
- Mar 2012
- Primary completion
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of atomoxetine in Mild Cognitive Impairment (MCI), sponsored by Emory University. Started Mar 2012; status: completed.
02
Drugs
atomoxetine
03
Conditions
Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on NCT01522404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01522404.